Excellent analysis of the REDUCE-IT study by @matthewherper, but there's one issue that I would like to point out as well https://www.forbes.com/sites/matthewherper/2018/11/10/fish-oil-derived-drug-shows-great-promise--with-big-caveats/#35596a333291 …
This is great because it allows us to calculate the cost-benefit of Vascepa for these endpoints Vascepa = ~$250 USD per month This equates to a 5-year cost of $15,000
-
-
Now we multiply that by the NNT = 21 21 patients * $15,000 = $315,000 cost to prevent one study endpoint
Show this thread -
Now this may be cost-effective - the composite "cardiovascular endpoint" score was derived from, among other things, death and heart attacks But it's worth noting that the medication is VERY expensive which offsets its usefulness a lot
Show this thread
End of conversation
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.